Forum Financial Management LP Raises Stock Position in GSK plc (NYSE:GSK)

Forum Financial Management LP lifted its holdings in shares of GSK plc (NYSE:GSK - Free Report) by 167.9% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 13,397 shares of the pharmaceutical company's stock after acquiring an additional 8,396 shares during the period. Forum Financial Management LP's holdings in GSK were worth $453,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the business. Michels Family Financial LLC acquired a new position in shares of GSK in the 4th quarter valued at $377,000. Formidable Asset Management LLC grew its stake in GSK by 27.3% during the 4th quarter. Formidable Asset Management LLC now owns 6,942 shares of the pharmaceutical company's stock valued at $235,000 after purchasing an additional 1,490 shares during the last quarter. Northwest Bank & Trust Co grew its stake in GSK by 1.3% during the 4th quarter. Northwest Bank & Trust Co now owns 22,405 shares of the pharmaceutical company's stock valued at $765,000 after purchasing an additional 289 shares during the last quarter. CSS LLC IL increased its holdings in shares of GSK by 150.2% in the fourth quarter. CSS LLC IL now owns 32,520 shares of the pharmaceutical company's stock valued at $1,100,000 after purchasing an additional 19,520 shares during the period. Finally, Continuum Advisory LLC raised its stake in shares of GSK by 14.0% in the fourth quarter. Continuum Advisory LLC now owns 12,080 shares of the pharmaceutical company's stock worth $409,000 after purchasing an additional 1,481 shares during the last quarter. Hedge funds and other institutional investors own 15.74% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on GSK shares. Wall Street Zen upgraded GSK from a "buy" rating to a "strong-buy" rating in a research report on Thursday, April 24th. BNP Paribas began coverage on shares of GSK in a research note on Tuesday, April 15th. They set a "neutral" rating and a $35.25 price objective for the company. Hsbc Global Res upgraded shares of GSK to a "strong sell" rating in a research note on Monday, April 28th. Finally, Morgan Stanley began coverage on shares of GSK in a report on Wednesday, February 12th. They set an "equal weight" rating for the company. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and four have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $40.58.

GSK Stock Performance

Shares of NYSE GSK traded up $0.84 during midday trading on Thursday, reaching $40.02. 5,048,071 shares of the stock were exchanged, compared to its average volume of 4,838,042. The company has a quick ratio of 0.52, a current ratio of 0.78 and a debt-to-equity ratio of 1.12. The firm has a market cap of $82.56 billion, a price-to-earnings ratio of 25.17, a PEG ratio of 1.12 and a beta of 0.51. The firm has a 50-day simple moving average of $37.26 and a two-hundred day simple moving average of $36.08. GSK plc has a twelve month low of $31.72 and a twelve month high of $45.01.

GSK (NYSE:GSK - Get Free Report) last released its quarterly earnings results on Wednesday, April 30th. The pharmaceutical company reported $1.13 EPS for the quarter, beating the consensus estimate of $1.08 by $0.05. GSK had a net margin of 8.13% and a return on equity of 48.59%. The company had revenue of $10.06 billion for the quarter, compared to analyst estimates of $7.52 billion. During the same quarter last year, the business earned $0.43 earnings per share. The firm's revenue was up 2.1% on a year-over-year basis. As a group, analysts anticipate that GSK plc will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, July 10th. Investors of record on Friday, May 16th will be paid a $0.4216 dividend. This represents a $1.69 annualized dividend and a dividend yield of 4.21%. The ex-dividend date is Friday, May 16th. This is a positive change from GSK's previous quarterly dividend of $0.39. GSK's payout ratio is currently 86.60%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.